Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate

Journal of Infectious Diseases

Volumn 197, Issue 6, 2008, Pages 795-802

  Prasad, Ananda S ^a   Beck, Frances W J ^a   Bao, Bin ^a   Snell, Diane ^a   Fitzgerald, James T ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR; ZINC ACETATE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN RHINOVIRUS; MALE; MOUTH DISEASE; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEETNESS; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADULT; COMMON COLD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; ZINC ACETATE;

EID: 40949163541     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/528803     Document Type: Article

References (28)

1. Dingle JH, Badger GF, Jordan WS Jr. Illness in the home: study of 25,000 illnesses in a group of Cleveland families. Cleveland, Ohio: Western Reserve University Press, 1964.
2. Gwaltney JM Jr, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med 1966; 275:1261-8.
3. Couch RB. The common cold control? J Infect Dis 1984; 150:167-73.
4. Turner RB. The treatment of rhinovirus infections: progress and potential. Antiviral Res 2001; 49:1-4.
5. Eby GA, Davis DR, Halcomb WW. Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 1984; 25:20-4.
6. Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tryrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 1987; 20:893-901.
7. Godfrey JC, Conant SB, Smith DS, Turco JH, Mercer N, Godfrey NH. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res 1992; 20:234-46.
8. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996; 125:81-8.
9. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. Curr Ther Res 1998; 59:595-606.
10. Farr BM, Conner EM, Betts RF, Oleske J, Minnefor A, Gwaltney JM Jr. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus cold. Antimicrob Agents Chemother 1987; 31:1183-7.
11. Douglas RM, Miles HB, Moore BW, Ryan P, Pinnock CB. Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infection of Australian adults. Antimicrob Agents Chemother 1987; 31:1263-5.
12. Smith DS, Helzner EC, Nuttall CE Jr, et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 1989; 33:646-8.
13. Weismann E, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold: a double-blind clinical trial. Dan Med Bull 1990; 37:279-81.
14. Macknin ML, Peidmonte M, Calendine C, Janosky J, Wald E. Zinc gluconate lozenges for treating common cold in children. JAMA 1998; 279:1962-7.
15. Turner RB, Cetnarowski WE. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clin Infect Dis 2000; 31:1202-8.
16. Prasad AS, Fitzgerald JT, Bao B, Beck FWJ, Chandrasekar PH. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. Ann Intern Med 2000; 133:245-52.
17. Eby GA. Linearity in dose-response from zinc lozenges in treatment of common colds. J Pharm Tech 1995; 11:110-22.
18. Eby GA. Zinc lozenges: cold cure or candy? Solution chemistry determinations. Bioscience Reports 2004; 24:23-39.
19. Novick SG, Godfrey JC, Godfrey NH, Wilder HR. How does zinc modify the common cold? Med Hypotheses 1996; 46:295-302.
20. Turner RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 1999; 281:1797-1804.
21. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the consort statement. JAMA 1996; 276:637-9.
22. Prasad AS. Techniques for measurement of zinc in biological samples. In: Biochemistry of zinc. New York: Plenum, 1993:279-89.
23. Prasad AS, Beck FWJ, Bao B, et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr 2007; 85:837-44.
24. Opal SM, De Palo VA. Anti-inflammatory cytokines. Chest 2000; 117:1162-72.
25. Prasad AS, Bao B, Beck FWJ, Kucuk O, Sarkar FH. Antioxidant effect of zinc in humans. Free Radic Biol Med 2004; 37:1182-90.
26. Beck FWJ, Prasad AS, Kaplan J, Fitzgerald JG, Brewer GJ. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. Am J Physiol 1997; 272:E1002-7.
27. Prasad AS. Zinc: mechanisms of host defense. J Nutr 2007; 137:1345-9.
28. Bao B, Prasad AS, Beck FWJ, Godmere M. Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 2003; 285:E1095-102.